Dystrophie musculaire de Duchenne Dystrophie musculaire de Duchenne Dystrophie musculaire de Duchenne

Archives

Monthly Archive for: "August, 2019"
Sarepta Therapeutics receives Complete Response Letter for golodirsen
By Marie
In News, Research, Treatments
Posted 22 August 2019

Sarepta Therapeutics receives Complete Response Letter for golodirsen

Sarepta Therapeutics receives Complete Response Letter from the US Food and Drug Administration for golodirsen New Drug Application Sarepta Therapeutics, Inc announced it had received a Complete [...]
All PolarisDMD sites are now launched
By Marie
In Research, Treatments
Posted 13 August 2019

All PolarisDMD sites are now launched

Catabasis announces that all 40 sites, across eight countries, are now fully launched for the Phase 3 PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy! La Force is happy to share [...]

Articles récents

  • The global day of giving
  • EMBARK, gene therapy for the treatment of DMD
  • Part B of MOMENTUM study of SRP-5051 in patients with DMD
  • World Duchenne Awareness Day 2021
  • ENDEAVOR, gene therapy for DMD

Catégories

  • Fundraising
  • in the Medias
  • News
  • Research
  • Testimonial
  • Treatments

+

Restez informé

    LA Force - Dystrophie musculaire de Duchenne

    La Force dmd - Tous droits réservés - Organisme de bienfaisance enregistré : 817683568RP0001
    La Force dmd La Force dmd
    • S’informer
      • Frequently Asked Questions
    • Make a Donation
    • Agir
      • Quick guige – Management of DMD
      • Take action – What’s your genetic profile?
      • Take action – Subscribe to registries
    • Aller plus loin
      • Go further – How can you access a new treatment?
      • Go further – How do researchers test new treatments?
      • Go further – How are drugs approved for use in Canada?
      • Go further – Who decides to reimburse drug costs?
    • Blog
    • About us
    • Contact-us